Biomarkers that can detect PD pathology and that can detect disease progression will be most helpful for patient care and proper clinical trial design. As part of the NINDS Parkinson's Disease Biomarkers Program, we seek to collect biological specimens from PD patients and identify serum biomarkers for disease identification and tracking disease progression.
Because the prevalence of Parkinson's disease (PD) is on the rise, it is a public health necessity that the disease be diagnosed at its earliest stage in a relatively non-invasive manner. Biomarkers that can detect PD pathology, and that can detect disease progression would be most helpful for patient care and for proper clinical trial design. The current project seeks to identify serum biomarkers for PD and collect clinical data and new biological specimens from PD patients as part of the NINDS Parkinson's Disease Biomarkers Program.
|Gwinn, Katrina; David, Karen K; Swanson-Fischer, Christine et al. (2017) Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomark Med 11:451-473|
|Yazdani, Umar; Zaman, Sayed; Hynan, Linda S et al. (2016) Blood biomarker for Parkinson disease: peptoids. NPJ Parkinsons Dis 2:|
|Rosenthal, Liana S; Drake, Daniel; Alcalay, Roy N et al. (2016) The NINDS Parkinson's disease biomarkers program. Mov Disord 31:915-23|
|Samudra, Niyatee; Patel, Neepa; Womack, Kyle B et al. (2016) Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management. Drugs Aging 33:855-863|
|Nalls, Mike A; McLean, Cory Y; Rick, Jacqueline et al. (2015) Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol 14:1002-9|
|Dewey, D Campbell; Miocinovic, Svjetlana; Bernstein, Ira et al. (2014) Automated gait and balance parameters diagnose and correlate with severity in Parkinson disease. J Neurol Sci 345:131-8|